Virica Biotech

The company notes that innate cellular antiviral defenses can hinder viral vector production efficiency, requiring approaches to overcome these barriers.

Virica Biotech Inc. will host a live webinar on November 14, 2022, focusing on process intensification in adeno-associated virus (AAV) vector manufacturing.

Virica Biotech joins the Canadian Pandemic Preparedness Hub, a research initiative funded by the Government of Canada to advance biomanufacturing and life sciences.

Virica Biotech expands its bioprocessing facilities in Ottawa with support from the Government of Ontario.

Virica Biotech collaborates with the Government of Canada to improve accessibility and affordability of gene therapies for Canadians.

Virica Biotech appoints Beth Thompson-Webb as Chief Commercial Officer to lead commercial efforts.

Virica Biotech collaborates with Oxford BioMedica to improve yield and production efficiency of lentiviral vector gene therapies.

Career opportunities in the biotechnology industry.

Viral Sensitizers (VSE) improve drug manufacturing process to deliver high yields at lower cost and enhance therapeutic effects.

Virica is the pioneer of a new product category of Viral Sensitizers (VSE) that remove the barriers to manufacturing effective viral medicines at scale.

Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.

Virica Biotech privacy policy.

Virica Biotech terms of use.

Virica introduces **Viric.AI**, a platform designed to streamline and accelerate the optimization of biomanufacturing processes. The tool targets inefficiencies in an industry known for slow, complex, and resource-heavy workflows. Virica aims to reduce development timelines and improve production efficiency through AI-driven solutions.

Apr 2026NewsfileNews article

Virica Biotech and FUJIFILM Biosciences are collaborating under the Canada–Japan Co-Innovation Program to develop solutions for scaling up Adeno-Associated Virus (AAV) vector production. The partnership aims to address manufacturing challenges that hinder cost-effective and accessible gene therapy treatments. AAV vectors are critical for in vivo gene therapies, and improving production efficiency could expand patient access.

Apr 2026cambridgenetwork.co.ukNews article

Virica Biotech and FUJIFILM Biosciences are partnering under Canada’s Japan Co-Innovation Program to develop solutions for adeno-associated virus (AAV) production bottlenecks. The collaboration aims to improve scalability and reduce manufacturing challenges in gene therapy, potentially accelerating patient access to treatments. AAV production remains a critical obstacle in the field.

Apr 2026Virica BiotechNews article

Six biotechnology companies form three strategic partnerships to tackle challenges in cell and gene therapy development. The collaborations aim to accelerate research and clinical applications in the field. Key focus areas include improving manufacturing processes and expanding therapeutic reach.

Oct 2024RegMedNetNews article